NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the …
Medical - Devices
US, Mountain View [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about NeuroPace, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | - | -1.881 | - | 44 | - | -48 | - | -24 | - | -25 | - | 38 |
| 2022 | -1.5600 | -1.968 | 45 | 45 | -38 | -50 | -28 | -23 | -23 | -24 | 38 | 38 |
| 2023 | -2.1700 | -1.362 | 45 | 64 | -53 | -35 | -36 | -33 | -40 | -35 | 51 | 55 |
| 2024 | -1.2700 | -1.006 | 65 | 79 | -32 | -26 | -22 | -41 | -27 | -43 | 54 | 68 |
| 2025 | - | -0.879 | - | 90 | - | -22 | - | -47 | - | -49 | - | 78 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |